REGENXBIO INC's ticker is RGNX and the CUSIP is 75901B107. A total of 3 filers reported holding REGENXBIO INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $510,719 | -32.5% | 30,582 | -18.4% | 0.00% | 0.0% |
| Q2 2023 | $756,539 | +30.8% | 37,471 | +20.6% | 0.00% | 0.0% |
| Q1 2023 | $578,399 | +57.2% | 31,080 | +88.4% | 0.00% | – |
| Q4 2022 | $367,840 | +12.1% | 16,495 | +35.0% | 0.00% | -100.0% |
| Q3 2022 | $328,000 | +56.2% | 12,219 | +45.4% | 0.00% | – |
| Q2 2022 | $210,000 | -34.6% | 8,406 | -11.8% | 0.00% | – |
| Q1 2022 | $321,000 | +4.2% | 9,533 | +22.4% | 0.00% | – |
| Q2 2021 | $308,000 | -35.8% | 7,788 | -44.6% | 0.00% | -100.0% |
| Q1 2021 | $480,000 | -70.8% | 14,063 | -68.5% | 0.00% | -66.7% |
| Q2 2020 | $1,642,000 | +656.7% | 44,578 | +743.8% | 0.00% | – |
| Q4 2019 | $217,000 | -13.2% | 5,283 | -24.8% | 0.00% | – |
| Q3 2019 | $250,000 | -20.9% | 7,021 | +14.4% | 0.00% | -100.0% |
| Q2 2019 | $316,000 | +3.9% | 6,138 | +15.6% | 0.00% | 0.0% |
| Q1 2019 | $304,000 | – | 5,309 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 839,139 | $35,177,000 | 6.39% |
| Sonic Fund II, L.P. | 188,786 | $7,914,000 | 4.47% |
| ArchPoint Investors | 297,355 | $12,465,000 | 3.73% |
| Redmile Group, LLC | 2,008,001 | $84,175,000 | 1.47% |
| RTW INVESTMENTS, LP | 1,845,366 | $77,358,000 | 1.17% |
| WS MANAGEMENT LLLP | 210,729 | $8,834,000 | 0.94% |
| FRAZIER MANAGEMENT LLC | 235,809 | $9,885,000 | 0.79% |
| Integral Health Asset Management, LLC | 55,000 | $2,306,000 | 0.66% |
| Sofinnova Investments, Inc. | 127,593 | $5,349,000 | 0.32% |
| HHLR ADVISORS, LTD. | 456,000 | $19,116,000 | 0.25% |